Nanocarrier-Based Delivery of SN22 as a Tocopheryl Oxamate Prodrug Achieves Rapid Tumor Regression and Extends Survival in High-Risk Neuroblastoma Models

Despite the use of intensive multimodality therapy, the majority of high-risk neuroblastoma (NB) patients do not survive. Without significant improvements in delivery strategies, anticancer agents used as a first-line treatment for high-risk tumors often fail to provide clinically meaningful results...

Descripción completa

Detalles Bibliográficos
Autores principales: Alferiev, Ivan S., Guerrero, David T., Soberman, Danielle, Guan, Peng, Nguyen, Ferro, Kolla, Venkatadri, Fishbein, Ilia, Pressly, Blake B., Brodeur, Garrett M., Chorny, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836113/
https://www.ncbi.nlm.nih.gov/pubmed/35163672
http://dx.doi.org/10.3390/ijms23031752

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836113/
https://www.ncbi.nlm.nih.gov/pubmed/35163672
http://dx.doi.org/10.3390/ijms23031752

Ejemplares similares